镓-68标记成纤维细胞活化蛋白抑制剂04 PET无创可视化肝纤维化:从临床前研究到临床转化
本研究采用镓-68标记成纤维细胞活化蛋白抑制剂04([68Ga]Ga-DOTA-FAPI-04)行micro-PET/CT,在四氯化碳诱导的小鼠肝纤维化模型(n=34)及橄榄油对照小鼠(n=26)中验证显像可行性,并纳入26例疑似或确诊肝纤维化患者行PET/MRI或PET/CT。结果显示小鼠肝脏摄取随纤维化进展升高,患者肝脏摄取与炎症分级(r=0.517至0.584,均P<0.05)及纤维化分期(r=0.653至0.698,均P<0.01)呈中度相关,平均SUVmax与本底比值在区分0期与1期方面优于肝脏硬度测定(AUC 0.984 vs 0.865)。
要点
- 小鼠肝脏[68Ga]Ga-DOTA-FAPI-04平均摄取从第6周0.70±0.11%ID/cc升至第10周峰值0.97±0.15%ID/cc,第12周略降至0.89±0.28%ID/cc。
- 患者肝脏摄取与炎症分级r=0.517至0.584(均P<0.05),与纤维化分期r=0.653至0.698(均P<0.01)。
- 平均SUVmax与本底比值区分0期与1期肝纤维化的AUC为0.984,优于肝脏硬度测定的0.865。
核心结论
- [68Ga]Ga-DOTA-FAPI-04 PET在临床前实验和初步临床试验中均显示出无创可视化和动态监测肝纤维化的显著潜力,尤其在早期阶段优于其他常用临床指标。
研究设计与样本
- 临床前研究对四氯化碳诱导的小鼠模型(n=34)和橄榄油处理的对照组(n=26)行[68Ga]Ga-DOTA-FAPI-04 micro-PET/CT,并验证探针生物分布。
- 临床试验纳入26例疑似或确诊肝纤维化患者,行[68Ga]Ga-DOTA-FAPI-04 PET/MRI或PET/CT,主要终点为肝脏摄取与组织学炎症分级和纤维化分期的相关性,以及与血清标志物和肝脏硬度测定(LSM)的诊断和鉴别效能比较。
- 试验注册号NCT04605939,注册日期2020年10月25日。
主要发现
- 小鼠肝脏[68Ga]Ga-DOTA-FAPI-04平均摄取显著高于对照组小鼠,从第6周0.70±0.11%ID/cc升高至第10周峰值0.97±0.15%ID/cc,第12周略降至0.89±0.28%ID/cc。
- 小鼠肝脏生物分布与FAP表达趋势一致。
- 患者肝脏[68Ga]Ga-DOTA-FAPI-04摄取与炎症分级呈中度相关(r=0.517至0.584,均P<0.05),与纤维化分期呈中度相关(r=0.653至0.698,均P<0.01)。
- 肝脏平均SUVmax与本底比值显示出优越的鉴别能力,尤其在0期与1期之间,优于LSM(AUC 0.984 vs 0.865)。
关键数值与推荐
- 临床前小鼠肝脏摄取以%ID/cc表示:第6周0.70±0.11,第10周0.97±0.15,第12周0.89±0.28。
- 患者肝脏摄取与炎症分级相关系数r=0.517至0.584(均P<0.05),与纤维化分期r=0.653至0.698(均P<0.01)。
- 平均SUVmax与本底比值区分0期与1期的AUC为0.984,LSM为0.865。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The reversibility of early liver fibrosis highlights the need for improved early detection and monitoring techniques. Fibroblast activation protein (FAP) is a promising theranostics target significantly upregulated during fibrosis. This preclinical and preliminary clinical study investigated a FAP-targeted probe, gallium-68-labeled FAP inhibitor 04 ([68Ga]Ga-DOTA-FAPI-04), for its capability to visualize liver fibrosis. METHODS: The preclinical study employed [68Ga]Ga-DOTA-FAPI-04 micro-positron emission tomography (PET)/computed tomography (CT) on carbon tetrachloride-induced mice model (n = 34) and olive oil-treated control group (n = 26), followed by validation of the probe's biodistribution. Hepatic uptake was correlated with fibrosis and inflammation levels, quantified through histology and serum assays. FAP and α-smooth muscle actin expression were determined by immunohistochemistry, as well as immunofluorescence. The subsequent clinical trial enrolled 26 patients with suspected or confirmed liver fibrosis to undergo [68Ga]Ga-DOTA-FAPI-04 PET/magnetic resonance imaging or PET/CT. Key endpoints included correlating [68Ga]Ga-DOTA-FAPI-04 uptake with histological inflammation grades and fibrosis stages, and evaluating its diagnostic and differential efficacy compared to established serum markers and liver stiffness measurement (LSM). RESULTS: [68Ga]Ga-DOTA-FAPI-04 mean uptake in mice livers was notably higher than in control mice, increasing from week 6 [0.70 ± 0.11 percentage injected dose per cubic centimeter (%ID/cc)], peaking at week 10 (0.97 ± 0.15%ID/cc) and slightly reducing at week 12 (0.89 ± 0.28%ID/cc). The hepatic biodistribution and FAP expression showed a consistent trend. In the patient cohort, hepatic [68Ga]Ga-DOTA-FAPI-04 uptake presented moderate correlations with inflammation grades (r = 0.517 to 0.584, all P < 0.05) and fibrosis stages (r = 0.653 to 0.698, all P < 0.01). The average SUVmax to background ratio in the liver showed superior discriminative ability, especially between stage 0 and stage 1, outperforming LSM (area under curve 0.984 vs. 0.865). CONCLUSION: [68Ga]Ga-DOTA-FAPI-04 PET shows significant potential for non-invasive visualization and dynamic monitoring of liver fibrosis in both preclinical experiment and preliminary clinical trial, especially outperforming other common clinical indicators in the early stage. TRIAL REGISTRATION: NCT04605939. Registered October 25, 2020, https://clinicaltrials.gov/study/NCT04605939.
引用
- Song Y, Qin C, Chen Y, et al. Non-invasive visualization of liver fibrosis with [68Ga]Ga-DOTA-FAPI-04 PET from preclinical insights to clinical translation. Eur J Nucl Med Mol Imaging. 2024. PMID: 38850311. doi:10.1007/s00259-024-06773-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。